Study guide

18.1 Risk Assessment and Centralised Surveillance

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

18.1 Risk Assessment and Centralised Surveillance

Key Takeaways Explain This Topic AI

Central surveillance can identify cross-site patterns needing investigation.

Unusual values or reporting rates are signals rather than proof of misconduct.

Effectiveness proportions require a relevant denominator and observation period.

Last updated: October 2026

Risk Assessment and Centralised Surveillance

An effectiveness criterion needs an observation period, denominator and reason for the chosen sample. In a hypothetical site review, 5 of 25 expected timed assessments were missed before remediation: 5/25 × 100 = 20% . After a scheduling change, the next 20 expected assessments are all documented within the protocol window: 0/20 = 0% missed in that observed period.

These figures describe the reviewed records; they do not prove that recurrence is permanently impossible or that no unreviewed record contains a problem.

Check that the new denominator includes every assessment actually expected under the defined review, rather than selecting only successful visits. Consider whether staff turnover, weekends or other circumstances that caused the original failure were represented. If the observed period contains no relevant high-risk activity, a zero-failure count may provide little evidence about the control.

Document implementation separately from effectiveness. A revised scheduler can be installed and staff trained while the first suitable effectiveness observations are still pending. The action tracker should show those different states honestly. If failures recur, reassess causes and the adequacy of the measure; do not change the success definition after seeing poor results simply to close the issue.

Risk-Based Monitoring (RBM), Centralized Monitoring & KRIs

Note

E6(R3) supports monitoring appropriate to the trial’s purpose, design, complexity, blinding, size, endpoints and relevant risks. The sponsor may choose on-site monitoring, a combination of on-site and centralized monitoring, or, where justified, centralized monitoring. The sponsor should document the rationale for the chosen monitoring strategy.

Monitoring should address the risks of the particular trial. Comparing transcribed values with source records is useful, but a matching value does not establish that consent was valid, an assessment occurred correctly, or a safety event was reported. Combine data verification with process review, central surveillance and other proportionate controls. No fixed budget saving or discrepancy-detection percentage establishes the right approach for every study.

A Practical Risk-Based Monitoring Framework

Operationalizing RBM requires a structured framework that links protocol risk assessment directly to monitoring execution. One possible operational approach, centers on three foundational components:

Structured Risk Assessment

Prior to trial finalization, a cross-functional sponsor team (clinical operations, biostatistics, medical affairs, data management, and QA) executes a formal structured risk assessment. The tool scores risks across multiple dimensions:

Protocol Complexity: Number of procedures per visit, volume of protocol-mandated blood draws, invasive biopsy requirements, and tightness of visit windows.

Subject Population Vulnerability: Pediatric, geriatric, critically ill, or incapacitated participants with diminished capacity to report adverse events.

Investigational Product (IP) Safety Profile: First-in-human biologics, narrow therapeutic windows, complex cold-chain storage, or hazardous reconstitution procedures.

Endpoint Objectivity: Objective automated lab markers (e.g., serum cholesterol) versus subjective clinical scales (e.g., pain scores or psychiatric evaluation ratings).

Site Operational Novelty: Experience level of investigators, unfamiliar electronic platforms, or decentralized home health nursing elements.

Identifying Critical-to-Quality (CtQ) Factors

From the RACT assessment, the study team isolates those critical data fields and processes that directly underpin subject safety and primary study conclusions. In a cardiovascular trial, CtQ data includes signed informed consent, primary major adverse cardiac event (MACE) endpoints, troponin levels, serious adverse events, and study drug dosing logs. Non-critical data—such as routine vital signs at non-dosing follow-up visits or minor demographic parameters—are deprioritized.

Constructing the Integrated Quality and Risk Management Plan (IQRMP)

The IQRMP establishes the operational monitoring plan, defining the specific blend of centralized monitoring, remote data surveillance, and targeted on-site CRA monitoring visits.

Centralized Monitoring vs. On-Site Monitoring vs. Remote Monitoring

Modern clinical trials deploy a multi-tiered monitoring architecture. The CCRA candidate must clearly distinguish the operational scope and technical capabilities of each monitoring modality:

Centralized Monitoring

Centralised monitoring can provide the statistical and analytical engine of RBM. Performed remotely by centralized monitors, clinical data managers, and biostatisticians, it evaluates aggregate clinical data accumulating across all participating investigative sites concurrently .

Core Capabilities of Centralized Monitoring:

Cross-Site Comparative Analytics: Comparing site performance metrics against national or global study means to detect statistical outliers.

Data Fabrication & Anomaly Detection:

Digit Preference Analysis: Human beings fabricating data rarely generate true random distributions. A central monitor evaluating blood pressure readings or laboratory numbers will identify sites where 80% of recorded systolic values end in "0" or "5," warranting review of rounding, instrument output and recording practices.

Zero-Variance Detection: Identifying investigative sites where repeated laboratory measurements or visual analog scales show unnaturally identical values across multiple subjects.

Visit Date Clustering: Detecting patterns where multiple subjects are recorded as attending complex clinical visits at identical weekend or holiday hours.

Underreporting Surveillance: Flagging sites that report zero adverse events, zero protocol deviations, or zero concomitant medications across large participant cohorts over extended treatment durations.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .